February 1, 2017
(Bloomberg) – Mylan NV set off a firestorm in Congress last year over skyrocketing prices of its EpiPen. Now it’s facing a U.S. antitrust investigation over whether it improperly thwarted competition to the blockbuster product. The company has received a request for information from the Federal Trade Commission as part of a preliminary investigation, it said Monday in response to a query from Bloomberg. It said it hasn’t acted improperly to prevent generic competition.